Resorcinol derivatives as human acetylcholinesterase inhibitor: An In Vitro and In Silico study

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

International Journal of Chemistry and Technology
Volume:5 Issue:2
Resorcinol derivatives as human acetylcholinesterase inhibitor: An In Vitro and In Silico study

Resorcinol derivatives as human acetylcholinesterase inhibitor: An In Vitro and In Silico study

Pages : 156-161

View : 38 | Download : 11

Publication Date : 2021-12-31

Article Type : Research Paper

Abstract :Inhibitors of Acetylcholinesterase insert ignore into journalissuearticles values(Acetylcholine acetylhydrolase, AChE, E.C.3.1.1.7); are highly significant in the treatment of neurodegenerative diseases such as Alzheimer’s disease insert ignore into journalissuearticles values(AD); due to the deep relationship with memory and acetylcholine. So investigation of natural AChE inhibitors having minimal side effects has become important. In this paper human erythrocytes AChE enzyme insert ignore into journalissuearticles values(0.032 EU mg-1 protein); was partially isolated by using DE-52 anion exchange chromatography. Then, primer effects of resorcinol derivatives on the enzyme activity were studied and IC50 values were found in the range of 2.74-363.61 µM. Besides, inhibition profiles were elucidated by molecular docking and the highest inhibition potency was observed in 4-hexylresorcinol with the free binding energy of -6.16 kcal mol-1. In conclusion, by using both in vitro and in silico approaches it was found that 4-hexylresorcinol had the highest inhibitory potential on human AChE. So, this compound may be used in drug design in memory-lost diseases.
Keywords : Acetylcholinesterase, resorcinol, inhibition, molecular docking

ORIGINAL ARTICLE URL

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.